Should physicians routinely screen patients for medication adherence, like antihypertensive therapy? Could that damage the physician-patient relationship?
There is at present no good way to assess patient adherence to hypertensive drug therapy; a concern since the rates of reported poor adherence are anywhere from 3 percent to 65 percent. Now, researchers at the University of Leicester in England believe they have found a way.
They used a high-performance liquid chromatography-tandem mass spectrometry-based urine analysis to assess how well patients were taking their blood pressure meds, reported MedPage Today.
The assay is able to detect levels for the 40 most-commonly prescribed antihypertensive medications - however cost is a concern. While a single test is $50 U.S. dollars, the analyzer itself is $250,000.
Would you use such a diagnostic test, if it were available, to screen your hypertensive patients who have a poor response to drug therapy? Do you think the cost of the test would outweigh the benefits?
Could such a test harm the physician-patient relationship by indicating that you don't trust your patients to tell you the truth?
Share your thoughts in the comments box below.
Asset Protection and Financial Planning
December 6th 2021Asset protection attorney and regular Physicians Practice contributor Ike Devji and Anthony Williams, an investment advisor representative and the founder and president of Mosaic Financial Associates, discuss the impact of COVID-19 on high-earner assets and financial planning, impending tax changes, common asset protection and wealth preservation mistakes high earners make, and more.
How to reduce surprise billing in your practice
November 15th 2021Physicians Practice® spoke with Kristina Hutson, a product line developer at Availity, about surprise billing events in independent healthcare practices and what owners and administrators can do to reduce the likelihood of their occurrence.